{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:35:49Z","timestamp":1781566549709,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.urology.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T23:23:19Z","timestamp":1611098599000},"page":"244-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"153","author":[{"given":"Grant","family":"Pollock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Hsieh","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Batai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chipollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2021.01.017_bib0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5527\/wjn.v5.i2.158","article-title":"Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management","volume":"5","author":"Fiuk","year":"2016","journal-title":"World J Nephrol"},{"key":"10.1016\/j.urology.2021.01.017_bib0002","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2021.01.017_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 Update","volume":"73","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.01.017_bib0004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005","volume":"107","author":"Raman","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2021.01.017_bib0005","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2021.01.017_bib0006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00345-016-1885-4","article-title":"Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer","volume":"35","author":"Pham","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2021.01.017_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clgc.2016.05.003","article-title":"Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"15","author":"Necchi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2021.01.017_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-017-0271-0","article-title":"Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma","volume":"5","author":"Kamat","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urology.2021.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.01.017_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0013","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2021.01.017_bib0014","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2021.01.017_bib0016","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.01.017_bib0017","doi-asserted-by":"crossref","first-page":"e15930","DOI":"10.1097\/MD.0000000000015930","article-title":"Is the extirpative surgery for primary tumor helpful for the patients with metastatic urothelial cancer at the time of diagnosis?","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urology.2021.01.017_bib0018","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","article-title":"Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database","volume":"3","author":"Moschini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0019","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/j.clgc.2019.03.003","article-title":"Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma","volume":"17","author":"Nazzani","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2021.01.017_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/JU.0000000000000172","article-title":"Optimizing the sequence of chemotherapy for upper tract urothelial carcinoma with clinically positive regional lymph nodes","volume":"202","author":"Chakiryan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2021.01.017_bib0021","doi-asserted-by":"crossref","first-page":"604.e9","DOI":"10.1016\/j.urolonc.2020.02.029","article-title":"Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database","volume":"38","author":"Singla","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0022","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.urology.2021.01.017_bib0023","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2021.01.017_bib0024","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.urology.2021.01.017_bib0025","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","article-title":"Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer","volume":"17","author":"Roberts","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0026","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2021.01.017_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bju.13860","article-title":"Cytoreductive nephrectomy in the era of targeted therapies: a review","volume":"120","author":"Pindoria","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2021.01.017_bib0029","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2019.04.007","article-title":"Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates?","volume":"2","author":"Larcher","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urology.2021.01.017_bib0030","doi-asserted-by":"crossref","unstructured":"Seisen T, Sun M, Leow JJ, et\u00a0al: Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score\u2013weighted analysis from the National Cancer Data Base. 34:3529-3536, 2016","DOI":"10.1200\/JCO.2016.66.7352"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429521000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:27:29Z","timestamp":1758767249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429521000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"alternative-id":["S0090429521000819"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2021.01.017","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}